Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KTE-X19 in Adult Japanese Subjects With Relapsed/Refractory MCL or B-ALL
NCT06253663Phase 2Active, not recruiting
- Sponsor
- Kite Pharma
- Start
- Mar 2024
- Primary completion
- Jul 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of brexucabtagene autoleucel in mantle cell lymphoma (MCL), B cell acute lymphoblastic leukemia (B-ALL), sponsored by Kite Pharma. Started Mar 2024; status: active, not recruiting.
02
Drugs
brexucabtagene autoleucel
03
Conditions
mantle cell lymphoma (MCL)B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06253663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06253663.